YAZ
LOE ApproachingNDAORALTABLET
Approved
Oct 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
5/8 — Partial
YAZ by Bayer is ovulation. Approved for symptoms of premenstrual dysphoric disorder (pmdd) in females of reproductive potential, moderate acne vulgaris in women at least 14 years of age. First approved in 2006.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YAZ is an oral contraceptive tablet approved by the FDA in 2006 and sponsored by Bayer. The product indication set is not specified in available data, but based on the oral tablet formulation and sponsor, it is a hormonal contraceptive. The mechanism of action involves suppression of ovulation through combined hormonal activity.
$0.114BPart D
LOE ApproachingProduct is in late-stage lifecycle with modest Part D claims, signaling a mature brand with smaller commercial team engagement.
Mechanism of Action
ovulation.
Worked on YAZ at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.